Loading...
01/11 16:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed sentiment. Financial performance shows strong revenue growth and margin improvement, but the anticipated operating loss and negative free cash flow raise concerns. The acquisition of TrueLark is positive, offering cross-sell opportunities and revenue growth potential. The Q&A reveals optimism about market resilience and product integration, but management's lack of clarity on payment solutions' growth potential adds uncertainty. Overall, the sentiment is balanced, leaning neutral due to financial strain and management's vague responses.
Revenue $55.8 million, an 18.3% year-over-year growth, driven by strong demand in Specialty Medical and payments revenue.
Gross Margin 72.1%, a 170 basis point improvement year-over-year, reflecting strong underlying unit economics and operational efficiency.
Gross Profit $40.2 million, up over $7 million or 21% year-over-year, driven by revenue growth and operational efficiencies.
Operating Income $39,000, an improvement of $1.4 million year-over-year, reflecting better revenue performance.
Adjusted EBITDA $1 million, improving by $1.4 million year-over-year due to revenue growth and operating efficiencies.
Cash and Short-term Investments $98.2 million, unchanged for Q1, with $25 million earmarked for the acquisition of TrueLark.
Free Cash Flow Negative $1.1 million, consistent with expectations due to elevated cash outflows from annual employee bonus payouts.
Sales and Marketing Expenses $21.7 million, or 39% of revenue, increased due to seasonal factors and the addition of sales reps.
Research and Development Expenses $8.8 million, or 16% of revenue, reflecting continued investment in solutions and practice management integrations.
General and Administrative Expenses $9.7 million, or 17% of revenue, an improvement year-over-year from 18% in Q1 2024, but increased sequentially due to seasonal factors.
Net Revenue Retention (NRR) 98%, consistent with last quarter and historical range, reflecting strong customer relationships.
Gross Revenue Retention (GRR) 91%, consistent with last quarter and historical range, indicating stability in customer retention.
Acquisition of TrueLark: Weave signed a definitive agreement to acquire TrueLark, an AI-powered receptionist and front-desk automation platform, for $35 million, comprising $25 million in cash and $10 million in equity.
Market Expansion: The acquisition of TrueLark expands Weave's addressable market to over $10 billion in the U.S. alone, enhancing their reach in the SMB healthcare sector.
Revenue Growth: Q1 revenue grew 18% year-over-year to $55.8 million, marking the 13th consecutive quarter of exceeding guidance.
Gross Margin Improvement: Gross margin improved to 72.1%, a 170 basis point increase year-over-year.
New Integrations: Weave launched three new integrations in Q1, increasing their integrated market by approximately 60,000 locations.
Focus on Automation: TrueLark's acquisition will enhance Weave's capabilities in automating routine tasks, allowing healthcare practices to focus on patient-centered engagement.
Leadership Addition: Abhi Sharma was appointed as Senior Vice President of Engineering, bringing expertise in AI-driven innovation.
Acquisition Risks: The acquisition of TrueLark for $35 million, comprising $25 million in cash and $10 million in equity, presents risks related to integration and performance-based equity awards tied to revenue milestones over the next two years.
Regulatory Compliance Risks: Weave anticipates incurring higher audit and compliance fees as they prepare for compliance with Section 404 of the Sarbanes-Oxley Act, which may impact operational costs.
Market Competition Risks: The company operates in a highly competitive market, facing pressures from other healthcare technology providers, which could affect customer acquisition and retention.
Economic Factors: Trade policy and tariffs may pose risks, although Weave has proactively managed hardware stock to mitigate potential impacts.
Operational Challenges: The company faces challenges related to staffing shortages in healthcare practices, which could affect the effectiveness of their solutions and customer satisfaction.
Financial Performance Risks: The anticipated non-GAAP operating loss for Q2 2025, including TrueLark expenses, indicates potential financial strain as the company invests in growth initiatives.
Acquisition of TrueLark: Weave signed a definitive agreement to acquire TrueLark for $35 million, comprising $25 million in cash and $10 million in equity. This acquisition aims to enhance Weave's platform with AI-powered automation, expanding its addressable market to over $10 billion in the U.S.
Growth in Specialty Medical: Weave reported strong demand in the Specialty Medical segment, achieving record sales and new customer acquisitions, particularly in MedSpa and Plastic Surgery.
Integration Strategy: Weave plans to leverage its go-to-market engine to extend TrueLark's reach in single location and small group practices, enhancing customer acquisition.
Investment in R&D and Sales/Marketing: Weave will invest in R&D for additional TrueLark integrations and in sales/marketing to drive demand and customer acquisition.
Q2 2025 Revenue Guidance: We expect total revenue for Q2 2025 to be in the range of $57.3 million to $58.3 million, with a small contribution from TrueLark.
Full Year 2025 Revenue Guidance: We are raising our full year revenue guidance to $236.8 million to $239.8 million, including an estimated $2.5 million from TrueLark.
Operating Income Guidance: We expect non-GAAP operating income for the year to be in the range of breakeven to $3 million, reflecting investments related to the TrueLark acquisition.
Acquisition of TrueLark: Weave acquired TrueLark for $35 million comprising $25 million in cash and $10 million in equity.
Performance-based equity awards: Established performance-based equity awards tied to revenue milestones for the next two years.
Weighted average share count: Expected to have a weighted average share count of approximately 76.5 million shares for the full year, which includes the effects of the TrueLark equity consideration.
The earnings call highlights strong financial performance, strategic growth through AI and partnerships, and optimistic guidance. While there are concerns about unclear management responses on payment adoption and future investments, the overall sentiment remains positive due to expected revenue growth, profitability improvements, and strategic initiatives. The market strategy and shareholder return plan are well-received, with plans for increased leverage and focus on high-potential verticals. Despite some uncertainties, the positive outlook on growth and profitability, along with strategic developments, suggests a positive stock price movement.
The earnings call highlights strong growth in specialty medical, successful integration of TrueLark, and positive customer feedback. The company's strategic investments in R&D and sales/marketing, along with raised revenue guidance, indicate a positive outlook. While there are some uncertainties regarding AI adoption and macroeconomic impacts, overall, the sentiment is positive due to strong demand, growth opportunities, and strategic plans. The Q&A section reinforces confidence in the company's direction, with analysts showing interest in growth strategies and integration progress.
The earnings call reveals strong financial performance with 18.3% revenue growth and improved gross margins. The acquisition of TrueLark is seen as a strategic complement, enhancing offerings and driving revenue. Despite increased expenses, operational efficiencies are evident with improved EBITDA. The Q&A section highlights resilience in market demand and competitive advantages. However, regulatory and operational risks are noted. Overall, the positive financial results, strategic acquisition, and market resilience suggest a positive stock price movement.
The earnings call presents a mixed sentiment. Financial performance shows strong revenue growth and margin improvement, but the anticipated operating loss and negative free cash flow raise concerns. The acquisition of TrueLark is positive, offering cross-sell opportunities and revenue growth potential. The Q&A reveals optimism about market resilience and product integration, but management's lack of clarity on payment solutions' growth potential adds uncertainty. Overall, the sentiment is balanced, leaning neutral due to financial strain and management's vague responses.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
